Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
1 result
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.
Neuro Oncol. 2023 Mar 14;25(3):566-579. doi: 10.1093/neuonc/noac183.
Neuro Oncol. 2023.
PMID: 35882450
Free PMC article.
Cite
Cite